@article{2d9a55e764d64b659a04fb1b1f86f121,
title = "Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group",
abstract = "The aim of this study was to learn the toxicity and efficacy of adding 4 doses of rituximab to a standard platinum-based salvage regimen for relapsed CD20+ B-cell non-Hodgkin lymphoma. Patients were treated with rituximab 375 mg/m2 days 1,8,15, 22 (cycle 1 only); cisplatin 100 mg/m2 over 24 h on day 3, cytosine arabinoside 2 g/m2 IV every 12 h × two doses on day 4, dexamethasone 40 mg PO/IV days 3-6, and G-CSF days 5-14. The ORR was 82% (47/57) with 33% (19/57) complete remissions and 49% (28/57) partial remissions. The duration of response (DR) for the 47 responders was 10.5 months (95% CI: 5.3-16.8). The median time to progression (TTP) was 10.3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP.",
keywords = "Non-Hodgkin lymphoma, Rituximab, Salvage chemotherapy, Transplant",
author = "Witzig, {Thomas E.} and Geyer, {Susan M.} and Kurtin, {Paul J.} and Colgan, {Joseph P.} and Inwards, {David J.} and Micallef, {Ivana N.M.} and LaPlant, {Betsy R.} and Michalak, {John C.} and Muhammad Salim and Dalton, {Robert J.} and Moore, {Dennis F.} and Reeder, {Craig B.}",
note = "Funding Information: This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-15083; CA-35269, CA-35431, CA-60276, CA-35267, CA-35195, CA-37417, CA-52352, CA-35101, CA-35448, CA-35415, CA-63849 from the National Cancer Institute, Department of Heath and Human Services. Additional participating institutions include: Carle Cancer Center CCOP, Urbana, IL 61801 (Kendrith M. Rowland, Jr, M.D.); Mer-itcare Hospital CCOP, Fargo, ND 58122 (Preston D. Steen, M.D.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld, M.D.); Iowa Oncology Research Association, Des Moines, IA 50309 (Roscoe F. Morton, M.D.); Geisinger Clinic & Medial Center CCOP, Danville, PA 17822 (Albert M. Bernath, Jr, M.D.); Toledo Community Hospital Oncology Program CCOP, Toledo, OH 43623 (Paul L. Schaefer, M.D.); Missouri Valley Cancer Consortium, Omaha, NE 68106 (Gamini S. Soori, M.D.).",
year = "2008",
month = jun,
doi = "10.1080/10428190801993470",
language = "English (US)",
volume = "49",
pages = "1074--1080",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",
}